Jillian Clare Kohler
Jillian Clare Kohler
Associate Professor, Leslie Dan Faculty of Pharmacy; Director of Global Health, Munk School of
Verified email at utoronto.ca - Homepage
TitleCited byYear
Promoting transparency in social science research
E Miguel, C Camerer, K Casey, J Cohen, KM Esterling, A Gerber, ...
Science 343 (6166), 30-31, 2014
How to achieve international action on falsified and substandard medicines
A Attaran, D Barry, S Basheer, R Bate, D Benton, J Chauvin, L Garrett, ...
Bmj 345, e7381, 2012
Globalization and social determinants of health: Promoting health equity in global governance (part 3 of 3)
R Labonté, T Schrecker
Globalization and health 3 (1), 7, 2007
Benchmarking and transparency: Incentives for the pharmaceutical industry’s corporate social responsibility
M Lee, J Kohler
Journal of Business Ethics 95 (4), 641-658, 2010
AIDS policy and pharmaceutical patents: Brazil's strategy to safeguard public health
JC Cohen, KM Lybecker
World Economy 28 (2), 211-230, 2005
Transparency in Nigeria's public pharmaceutical sector: perceptions from policy makers
HA Garuba, JC Kohler, AM Huisman
Globalization and health 5 (1), 14, 2009
Orphan drug policies: implications for the United States, Canada, and developing countries
RY Cheung, JC Cohen, P Illingworth
Health LJ 12, 183, 2004
The dilemma of intellectual property rights for pharmaceuticals: the tension between ensuring access of the poor to medicines and committing to international agreements
JC Cohen, P Illingworth
Developing world bioethics 3 (1), 27-48, 2003
The morally uncomfortable global drug gap
JC Cohen‐Kohler
Clinical Pharmacology & Therapeutics 82 (5), 610-614, 2007
Public policies in the pharmaceutical sector: a case study of Brazil
JC Cohen
World Bank, 2000
Smoking cessation and nicotine-replacement therapies
TE Novotny, JC Cohen, A Yurekli, D Sweanor, J De Beyer
The role of supportive supervision on immunization program outcome-a randomized field trial from Georgia
M Djibuti, G Gotsadze, A Zoidze, G Mataradze, LC Esmail, JC Kohler
BMC international health and human rights 9 (1), S11, 2009
Corruption and pharmaceuticals: Strengthening good governance to improve access
JC Cohen, MF Mrazek, L Hawkins
The many faces of corruption: tracking vulnerabilities at the sector level …, 2007
Tackling corruption in the pharmaceutical systems worldwide with courage and conviction
JC Cohen, M Mrazek, L Hawkins
Clinical Pharmacology & Therapeutics 81 (3), 445-449, 2007
Pharmaceuticals and corruption: a risk assessment
JC Cohen
Global Corruption Report 2006, 77-84, 2006
World Bank Pharmaceuticals
R Govindaraj, MR Reich, JC Cohen
World Bank, Washington, DC, 2000
An examination of pharmaceutical systems in severely disrupted countries
JC Kohler, E Pavignani, M Michael, N Ovtcharenko, M Murru, PS Hill
BMC International Health and Human Rights 12 (1), 34, 2012
TRIPS, the Doha Declaration and increasing access to medicines: policy options for Ghana
JC Cohen, M Gyansa-Lutterodt, K Torpey, LC Esmail, G Kurokawa
Globalization and health 1 (1), 17, 2005
The danger of imperfect regulation: OxyContin use in the United States and Canada
J Lexchin, JC Kohler
International Journal of Risk & Safety in Medicine 23 (4), 233-240, 2011
Addressing legal and political barriers to global pharmaceutical access: Options for remedying the impact of the Agreement on Trade-Related Aspects of Intellectual Property …
JC Cohen-Kohler, L Forman, N Lipkus
Health Economics, Policy and Law 3 (3), 229-256, 2008
The system can't perform the operation now. Try again later.
Articles 1–20